AROA Biosurgery Strikes Exclusive U.S. Co-Promotion Deal with Mölnlycke for Endoform Wound Care Line

Aroa Biosurgery Ltd (ARX.AX) announced an exclusive agreement with Mölnlycke Healthcare US to co-promote its Endoform wound care products in U.S. post-acute care settings. The New Zealand-based soft tissue regeneration company said the deal pairs its AROA ECM technology with Mölnlycke's wound care expertise and distribution network to expand reach and support future growth. Under the agreement, AROA retains ownership of the Endoform product line and proprietary ECM technology while continuing to manufacture, distribute and supply the products. The arrangement is expected to let the company focus on expanding adoption of Myriad in surgical applications and advancing Symphony's commercial opportunity in outpatient wound care. The agreement is limited to Endoform's U.S. post-acute care business and does not affect AROA's other products, commercial agreements or international Endoform distribution. AROA reaffirmed FY2027 guidance of NZ$115 million to NZ$125 million in total revenue and NZ$8 million to NZ$11 million in normalised EBITDA. ARX.AX closed Tuesday's trade at A$0.51 and was recently down 0.98% at A$0.50. The stock has traded between A$0.47 and A$0.80 over the past 52 weeks.